Search for drugs:
Typing the drug name to query
DEFERIPRONE
DIR Classification
Classification:Ambiguous
Severity Score:1.0
Description in Drug Labeling: View Full Labeling: SPL in DailyMed | PDF
- CLINICAL PHARMACOLOGY
- Pharmacodynamics
- Cardiac Electrophysiology
- At the maximum approved recommended dose, deferiprone does not prolong the QT interval to any clinically relevant extent.
Postmarketing Surveillance
Contingency Table:
Current Drug
Other Drugs
QT Prolongation
1
24091
Other ADRs
2156
38379431
Odds Ratio = 0.739
Drug Property Information
ATC Code(s):
- V03AC02 - deferiprone
- V03AC0 -
- V03AC - Iron chelating agents
- V03A - ALL OTHER THERAPEUTIC PRODUCTS
- V03 - ALL OTHER THERAPEUTIC PRODUCTS
- V - VARIOUS
Active Ingredient:DEFERIPRONE
Active Ingredient UNII:2BTY8KH53L
Drugbank ID:DB08826
PubChem Compound:2972
CTD ID:D000077543
PharmGKB:PA166118041
CAS Number:30652-11-0
Dosage Form(s):tablet
Route(s) Of Administrator:oral
Daily Dose:
Chemical Structure: 
SMILE Code:
CN1C=CC(=O)C(O)=C1C
CN1C=CC(=O)C(O)=C1C
Reference
N/A
Disclaimer:
The content of this database of QT prolongation is intended for educational and scientific research purposes only. It is not intended as a substitute for professional medical advice, diagnosis or treatment.
Any mention of commercial products is for clarification and not intended as endorsement.